FR2557797A1 - Terminalia chebula-based therapeutic composition for the oral treatment of psoriasis - Google Patents

Terminalia chebula-based therapeutic composition for the oral treatment of psoriasis Download PDF

Info

Publication number
FR2557797A1
FR2557797A1 FR8400225A FR8400225A FR2557797A1 FR 2557797 A1 FR2557797 A1 FR 2557797A1 FR 8400225 A FR8400225 A FR 8400225A FR 8400225 A FR8400225 A FR 8400225A FR 2557797 A1 FR2557797 A1 FR 2557797A1
Authority
FR
France
Prior art keywords
weight
parts
terminalia chebula
mixture
linum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8400225A
Other languages
French (fr)
Other versions
FR2557797B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHEIKHO ZAHIRA
Original Assignee
CHEIKHO ZAHIRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHEIKHO ZAHIRA filed Critical CHEIKHO ZAHIRA
Priority to FR8400225A priority Critical patent/FR2557797B1/en
Publication of FR2557797A1 publication Critical patent/FR2557797A1/en
Application granted granted Critical
Publication of FR2557797B1 publication Critical patent/FR2557797B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The subject of the invention is a therapeutic composition for the treatment of psoriasis which can be administered orally, characterised in that it comprises, as active ingredient, an aqueous extract obtained from a mixture of Terminalia chebula, Foeniculum vulgare mill and Linum usitatissinum, the mixture comprising 2 to 40 parts by weight of Foeniculum vulgare mill and 3 to 60 parts by weight of Linum usitatissinum per 100 parts by weight of Terminalia chebula.

Description

La présente invention concerne une composition therapeutiqMe pour le traitement du psoriasis, et administrable à 1'homme par voie orale
La composition selon la présente invention comprend à titre de principe actif un extrait aqueux obtenu à partir d'un mélange de Terminalia Chebula, Foeniculum Vulgare
Mill et de Linum Usitatissinum, le mélange comprenant de 2 à 40 parties en poids de Foeniculum Vulgare Mill et de 3 à 60 parties en poids de Linum Usitatissinum pour 100 parties en poids de Terminalia Chebula.The present invention relates to a therapeutic composition for the treatment of psoriasis, which can be administered to humans by the oral route.
The composition according to the present invention comprises, as active principle, an aqueous extract obtained from a mixture of Terminalia Chebula, Foeniculum Vulgare
Mill and Linum Usitatissinum, the mixture comprising from 2 to 40 parts by weight of Foeniculum Vulgare Mill and from 3 to 60 parts by weight of Linum Usitatissinum per 100 parts by weight of Terminalia Chebula.

Terminalia Chebula ou myrobalan chebulinique est constitue des fruits d'une série d'espèces de Terminalia. Terminalia Chebula or chebulinic myrobalan is the fruit of a series of Terminalia species.

Il se compose essentiellement de tannins. On trouvera une description de Terminalia Chebula notamment dans l'ouvrage de Saida Qaiser et M. Qaiser, Flora of West Pakistan nb 122.It mainly consists of tannins. One will find a description of Terminalia Chebula in particular in the work of Saida Qaiser and M. Qaiser, Flora of West Pakistan nb 122.

Foeniculum Vulgare Mill est constitué par des graines qui contiennent de 3 à 6 % en poids d'huiles volatiles, jusqu'à 20 % en poids d'utiles grasses, 3 à 5 % en poids de glucides et j-usqu'à 20 % en poids d'éléments protidiques. On trouvera une description de ces graines dans l'ouvrage de Mohammed Al Aoudate et Georges Lahham, Les plantes médicinales en Syrie, 1977, Al Khansaa. Foeniculum Vulgare Mill consists of seeds that contain 3 to 6% by weight of volatile oils, up to 20% by weight of fatty oils, 3 to 5% by weight of carbohydrates and up to 20% by weight of protein elements. A description of these seeds can be found in the work of Mohammed Al Aoudate and Georges Lahham, Medicinal plants in Syria, 1977, Al Khansaa.

Linum Usitatissinum est constitué par des graines de lin. On trouvera une description de Linum Usitatissinum dans la Pharmacopée Française. Linum Usitatissinum is made up of flax seeds. A description of Linum Usitatissinum can be found in the French Pharmacopoeia.

Dans une forme préférée de réalisation de l'invention, l'extrait aqueux est obtenu à partir d'un mélange contenant en outre de 4 a 50 parties en poids de levure de bière pour 100 parties en poids de Terminalia Chebula. In a preferred embodiment of the invention, the aqueous extract is obtained from a mixture additionally containing from 4 to 50 parts by weight of brewer's yeast per 100 parts by weight of Terminalia Chebula.

De plus, de préférence, l'extrait aqueux est obtenu à partir d'un mélange contenant de 2,5 à 15 parties en poids d'amidon de riz en poudre.  In addition, preferably, the aqueous extract is obtained from a mixture containing from 2.5 to 15 parts by weight of powdered rice starch.

Pour obtenir l'extrait on traite les constituants du mélange par de l'eau à ébullition pendant une durée de quelques minutes à quelques heures. La quantité d'eau représente avantageusement de 2 à 20 fois la quantité de
Terminalia Chebula.To obtain the extract, the constituents of the mixture are treated with boiling water for a period of several minutes to several hours. The amount of water advantageously represents from 2 to 20 times the amount of
Terminalia Chebula.

L'extrait peut etre concentré si nécessaire. The extract can be concentrated if necessary.

La composition pharmaceutique peut en outre contenir des excipients et notamment des édulcorants, tels que du saccharose ou du miel. The pharmaceutical composition can also contain excipients and in particular sweeteners, such as sucrose or honey.

La composition peut ainsi se présenter sous forme de sirop ou de produit pratiquement solide en augmentant la quantité d'excipient. The composition can thus be in the form of a syrup or a practically solid product by increasing the amount of excipient.

Dans une variante de l'invention, la composition contient non pas un extrait aqueux mais une poudre contenant les mêmes constituants que celui du mélange utilisé pour l'extraction, mais à l'état broyé. In a variant of the invention, the composition contains not an aqueous extract but a powder containing the same constituents as that of the mixture used for the extraction, but in the ground state.

Dans ce cas, la composition peut contenir divers excipients appropriés convenant pour la forme choisie, qui peut être des comprimés, des-gélules, des dragées, des capsules. In this case, the composition can contain various suitable excipients suitable for the chosen form, which can be tablets, gelatin capsules, dragees, capsules.

Lors d'essais chez lthomme, la composition selon l'invention a permis d'obtenir une disparition des plaques chez des personnes souffrant de psoriasis. Aucun signe de toxicité n'a été décelé sur une période prolongée. During tests in humans, the composition according to the invention has made it possible to obtain a disappearance of the plaques in people suffering from psoriasis. No signs of toxicity have been detected over an extended period.

On donnera ci-après des exemples de compositions thérapeutiques. Examples of therapeutic compositions will be given below.

EXEMPLE 1
On ajoute à 500 parties en poids d'eau les constituants suivants
- Terminalia Chebula 100 parties en poids
- Foeniculum Vulgare Mill 20
- Linum Usitatissinum 15 "
- Amidon de riz 10
- Levure de bière 10
On fait bouillir pendant 3 heures, en laissant évaporer une partie de l'eau, puis on filtre. Au liquide séparé par filtration(75 à 85 parties en poids),,on ajoute 50 parties en poids de saccharose. On fait bouillir pendant 15 minutes, puis on conditionne en bouteilles. Le sirop obtenu est utilisé à la dose journalière de 150 à 350 ml pour le traitement du psoriasis.EXAMPLE 1
The following constituents are added to 500 parts by weight of water
- Terminalia Chebula 100 parts by weight
- Foeniculum Vulgare Mill 20
- Linum Usitatissinum 15 "
- Rice starch 10
- Brewer's yeast 10
It is boiled for 3 hours, leaving part of the water to evaporate, then filtered. To the liquid separated by filtration (75 to 85 parts by weight), 50 parts by weight of sucrose are added. It is boiled for 15 minutes, then it is packaged in bottles. The syrup obtained is used at a daily dose of 150 to 350 ml for the treatment of psoriasis.

EXEMPLE 2
On opère comme à l'exemple 1, mais à l'extrait liquide obtenu on ajoute une quantité double de miel, on chauffe à ébullition et on mélange. On refroidit et on coupe pour obtenir des morceaux.EXAMPLE 2
The procedure is as in Example 1, but to the liquid extract obtained a double quantity of honey is added, the mixture is heated to boiling and mixed. It is cooled and cut to obtain pieces.

EXEMPLE 3
On broie les constituants suivants jusqu'à une taille inferieure à 0,3 mm:
- Terminalia Chebula 100 parties en poids
- Foeniculum Vulgare Mill 20
- Linum Usitatissinum 15 " I'
- Amidon de riz 10
- Levure de bière 10
On conditionne la poudre dans des capsules. EXAMPLE 3
The following components are ground to a size less than 0.3 mm:
- Terminalia Chebula 100 parts by weight
- Foeniculum Vulgare Mill 20
- Linum Usitatissinum 15 "I '
- Rice starch 10
- Brewer's yeast 10
The powder is packaged in capsules.

Claims (7)

REVENDICATIONS 1. Composition thérapeutique pour le traitement du psoriasis et administrable par voie orale, caractérisée en ce qu'elle comprend à titre de principe actif un extrait aqueux obtenu à partir d'un mélange de Terminalia Chebula, 1. Therapeutic composition for the treatment of psoriasis and which can be administered orally, characterized in that it comprises, as active principle, an aqueous extract obtained from a mixture of Terminalia Chebula, Foeniculum Vulgare Mill et de Linum Usitatissinum, le mélange comprenant de 2 à 40 parties en poids de Foeniculum Vulgare Mill et de 3 à 60 parties en poids de LinumFoeniculum Vulgare Mill and Linum Usitatissinum, the mixture comprising from 2 to 40 parts by weight of Foeniculum Vulgare Mill and from 3 to 60 parts by weight of Linum Usitatissinum pour 100 parties en poids de TerminaliaUsitatissinum per 100 parts by weight of Terminalia Chebula.Chebula. 2. Composition selon la revendication 1, caractérisée en ce que l'extrait aqueux est obtenu à partir d'un mélange contenant en outre de 4 à 50 parties en poids de levure de bière pour 100 parties en poids de Terminalia 2. Composition according to claim 1, characterized in that the aqueous extract is obtained from a mixture additionally containing from 4 to 50 parts by weight of brewer's yeast per 100 parts by weight of Terminalia Chebula.Chebula. 3. Composition selon la revendication 1 ou la revendication 2, caractérisée en ce que l'extrait aqueux est obtenu à partir d'un mélange contenant en outre de 2,5 a 15 parties en poids d'amidon de riz en poudre pour 100 parties en poids de Terminalia Chebula. 3. Composition according to claim 1 or claim 2, characterized in that the aqueous extract is obtained from a mixture additionally containing from 2.5 to 15 parts by weight of powdered rice starch per 100 parts by weight of Terminalia Chebula. 4. Composition selon l'une quelconque des revendications 1 à 3, caractérisée en ce que l'extrait aqueux contient un édulcorant. 4. Composition according to any one of claims 1 to 3, characterized in that the aqueous extract contains a sweetener. 5. Composition thérapeutique pour le traitement du psoriasis et administrable par voie orale, caractérisée en ce qu'elle comprend à titre de principe actif une poudre contenant à l'état broyé un mélange de Terminalia Chebula, 5. Therapeutic composition for the treatment of psoriasis and which can be administered orally, characterized in that it comprises, as active principle, a powder containing in the ground state a mixture of Terminalia Chebula, Foeniculum Vulgare et Mill et de Linum Usitatissinum, le mélange comprenant de 3 à 40 parties en poids de FoeniculumFoeniculum Vulgare and Mill and Linum Usitatissinum, the mixture comprising from 3 to 40 parts by weight of Foeniculum Vulgare Mill et de 3 à 60 parties en poids de Linum Usitatissinun pour 100 parties en poids de Terminalia Chebula.Vulgare Mill and from 3 to 60 parts by weight of Linum Usitatissinun per 100 parts by weight of Terminalia Chebula. 6. Composition selon la revendication 5, caractérisée en ce qu'elle contient en outre de 4 à 50 parties en poids de levure de bière pour 100 parties en poids de Terminalia Chebula.  6. Composition according to claim 5, characterized in that it also contains from 4 to 50 parts by weight of brewer's yeast per 100 parts by weight of Terminalia Chebula. 7. Composition selon la revendication 5 ou la revendication 6, caractérisé en ce qu'elle contient en outre de 2,5 à 15 parties en poids d'amidon de riz en poudre pour 100 parties en poids de Terminalia Chebula.  7. Composition according to claim 5 or claim 6, characterized in that it also contains 2.5 to 15 parts by weight of powdered rice starch per 100 parts by weight of Terminalia Chebula.
FR8400225A 1984-01-09 1984-01-09 THERAPEUTIC COMPOSITION BASED ON TERMINALIA CHEBULA FOR THE TREATMENT OF PSORIASIS ORALLY. Expired FR2557797B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR8400225A FR2557797B1 (en) 1984-01-09 1984-01-09 THERAPEUTIC COMPOSITION BASED ON TERMINALIA CHEBULA FOR THE TREATMENT OF PSORIASIS ORALLY.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8400225A FR2557797B1 (en) 1984-01-09 1984-01-09 THERAPEUTIC COMPOSITION BASED ON TERMINALIA CHEBULA FOR THE TREATMENT OF PSORIASIS ORALLY.

Publications (2)

Publication Number Publication Date
FR2557797A1 true FR2557797A1 (en) 1985-07-12
FR2557797B1 FR2557797B1 (en) 1986-05-30

Family

ID=9299928

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8400225A Expired FR2557797B1 (en) 1984-01-09 1984-01-09 THERAPEUTIC COMPOSITION BASED ON TERMINALIA CHEBULA FOR THE TREATMENT OF PSORIASIS ORALLY.

Country Status (1)

Country Link
FR (1) FR2557797B1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804431A1 (en) * 1987-02-13 1988-08-25 Doryokuro Kakunenryo METHOD FOR TREATING RADIOACTIVE LIQUID WASTE
WO1988009178A1 (en) * 1987-05-18 1988-12-01 Vladimir Badmajew Pharmaceutical preparation
EP0511181A1 (en) * 1991-04-10 1992-10-28 Camurus Ab Saliva substitute
EP0517836A1 (en) * 1990-03-02 1992-12-16 The Partnership Of Isaac G. Eliaz And Shmuel Gonen Method and product for promoting hair growth and treating skin conditions
US6203782B1 (en) 1990-03-02 2001-03-20 Universal Biologics, Inc. Method and product for promoting hair growth and treating skin conditions
WO2006022502A1 (en) 2004-08-23 2006-03-02 Neurogenex Co., Ltd. Compounds with diphenoyl -structure for the treatment of immune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, volume 95, no. 8, 24 août 1981, page 391, abrégé 68027f (COLUMBUS, Ohio, US) & CS - A - 185 262 (JANOSIK, IGOR) 15-09-1980 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3804431A1 (en) * 1987-02-13 1988-08-25 Doryokuro Kakunenryo METHOD FOR TREATING RADIOACTIVE LIQUID WASTE
WO1988009178A1 (en) * 1987-05-18 1988-12-01 Vladimir Badmajew Pharmaceutical preparation
EP0517836A1 (en) * 1990-03-02 1992-12-16 The Partnership Of Isaac G. Eliaz And Shmuel Gonen Method and product for promoting hair growth and treating skin conditions
EP0517836A4 (en) * 1990-03-02 1993-09-15 Isaac G. Eliaz & Shmuel Gonen Partnership Method and product for promoting hair growth and treating skin conditions
US6203782B1 (en) 1990-03-02 2001-03-20 Universal Biologics, Inc. Method and product for promoting hair growth and treating skin conditions
EP0511181A1 (en) * 1991-04-10 1992-10-28 Camurus Ab Saliva substitute
US5260282A (en) * 1991-04-10 1993-11-09 Camurus Ab Saliva substitute
WO2006022502A1 (en) 2004-08-23 2006-03-02 Neurogenex Co., Ltd. Compounds with diphenoyl -structure for the treatment of immune diseases
EP1789034A1 (en) * 2004-08-23 2007-05-30 Neurogenex Co., Ltd. Compounds with diphenoyl -structure for the treatment of immune diseases
EP1789034A4 (en) * 2004-08-23 2009-11-11 Neurogenex Co Ltd Compounds with diphenoyl -structure for the treatment of immune diseases

Also Published As

Publication number Publication date
FR2557797B1 (en) 1986-05-30

Similar Documents

Publication Publication Date Title
BE895724A (en) NEW THERAPEUTIC USE OF DIHYDROCYCLOSPORIN D
JP2000086510A (en) Histamine release inhibitor
EP1014927B1 (en) Use of shogaols and gingerols for preparing deodorant compositions
JPH07274894A (en) Food/beverage for preventing gastric ulcer
JPH08225453A (en) Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same
EP0349469A1 (en) Pharmaceutical product having skin regenerating properties based on the active principle of mimosa tenuiflora, and process for producing same
JP4002654B2 (en) Blood lipid improving agent, cyclic AMP phosphodiesterase inhibitor, obesity preventive / eliminating agent, food and beverage, and skin external preparation
FR2557797A1 (en) Terminalia chebula-based therapeutic composition for the oral treatment of psoriasis
JP6778026B2 (en) Whitening agents and whitening foods and drinks containing 4'-demethylnobiletin as an active ingredient
KR100577677B1 (en) Composition for lowering blood glucose
LU87169A1 (en) PHARMACEUTICAL COMPOSITIONS ACTING ON THE HEART AND THE CARDIOVASCULAR SYSTEM AND PROCESS FOR THEIR PREPARATION
JP6122200B1 (en) Anti-glycation composition
JP2005052085A (en) Food composition
EP0075523A1 (en) Medicaments based on algae, and formulations thereof
FR2714054A1 (en) 4-Hydroxy-5-methyl-3-Ý2H¨-furanone extn. from Pinaceae
EP0679087B1 (en) Cosmetic or pharmaceutical and particularly dermatological composition containing a vismia extract
JP2004137218A (en) Lipolysis promoter, and skin care preparation for external use and food and drink product using the same
JP3455436B2 (en) How to make antioxidants
JP2724318B2 (en) Composition for removing bad breath
JP2006160625A (en) Water-soluble extract derived from bee larva having protease inhibitory action, method for producing the same, and product containing the same
JPH08208501A (en) Anti-hericobacter pylori medicine containing extract of garcinia mangostana l.
JP4623996B2 (en) Antihypertensive agent containing tamogi mushroom extract as active ingredient
WO1994015626A9 (en) Cosmetic or pharmaceutical and particularly dermatological composition containing a vismia extract
JP2019182863A (en) Skin firmness or moisture improving composition
KR102281794B1 (en) Composition for protecting hepatic damage on heavy metal comprising extracts from Dendropanax morbifera

Legal Events

Date Code Title Description
ST Notification of lapse